Use of cardioprotective medications in kidney transplant recipients

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1811-1815

  Gaston, R S ^a   Kasiske, B L ^b   Fieberg, A M ^c   Leduc, R ^c   Cosio, F C ^d   Gourishankar, S ^e   Halloran, P ^e   Hunsicker, L ^f   Rush, D ^g   Matas, A J ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiovascular complications; Hypertension; Kidney transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; GRAFT RECIPIENT; HEART PROTECTION; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CANADA; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; UNITED STATES;

EID: 67650941470     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02696.x     Document Type: Article

References (14)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289 1295.
2. United States Renal Data System. USRDS 2008 Annual Data Report. 2008 [cited October 15, 2008]; Available from : http://www.usrds.org
3. Meier-Kriesche HU, Schold JD, Gaston RS, Wadstrom J, Kaplan B. Kidneys from deceased donors: Maximizing the value of a scarce resource. Am J Transplant 2005 5 : 1725 1730.
4. Wolfe RA, McCullough KP, Schaubel DE et al. Calculating life years from transplant (LYFT): Methods for kidney and kidney-pancreas candidates. Am J Transplant 2008 8 (4 Pt 2 997 1011.
5. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002 360 : 2 3.
6. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003 75 (10 Suppl SS3 SS24.
7. Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004 4 (Suppl 7 13 53.
8. Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004 43 : 1071 1081.
9. Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 2005 5 : 2236 2243.
10. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004 4 : 1514 1522.
11. Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 2005 5 : 2929 2936.
12. Jardine AG, Fellstrom B, Logan JO et al. Cardiovascular risk and renal transplantation: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005 46 : 529 536.
13. Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 337 : a1840.
14. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008 300 : 2134 2141.